Alvotech secures U.S. rights for its proposed Humira biosimilar.
- Expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
- All ongoing U.S. disputes between AbbVie and Alvotech have been resolved, including the ITC action brought forth in December
- NOTE: Dec. 7,
Alvotech Going Public Through Oaktree SPAC Merger
NOTE
- AbbVie Inc. rose 0.0% in postmarket trading to $147.19 as of 5:10 p.m. New York time
- The average 12-month price target of $152.55 is 3.6% above the current price
- 18 buys, 7 holds, 1 sells
To view the source of this information, click